Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
ZYNE Price/Volume Stats
| Current price | $1.32 | 52-week high | $1.40 |
| Prev. close | $1.34 | 52-week low | $0.25 |
| Day low | $1.32 | Volume | 1,099,200 |
| Day high | $1.33 | Avg. volume | 471,750 |
| 50-day MA | $0.94 | Dividend yield | N/A |
| 200-day MA | $0.57 | Market Cap | 71.20M |
ZYNE Stock Price Chart Interactive Chart >
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
Latest ZYNE News From Around the Web
Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals IncOn September 13, 2023, President Terri Sebree of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) sold 12,401 shares of the company's stock. |
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research SymposiumZygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q)DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsy |
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications. |
Harmony Biosciences to acquire Main Line's Zynerba in up to $200M dealThe centerpiece of Harmony Biosciences' deal is Zynerba's lead new drug candidate Zygel, a pharmaceutically produced transdermal cannabinoid therapy. |
ZYNE Price Returns
| 1-mo | -0.38% |
| 3-mo | 300.49% |
| 6-mo | 213.24% |
| 1-year | 60.98% |
| 3-year | -59.76% |
| 5-year | -83.16% |
| YTD | 149.06% |
| 2022 | -81.60% |
| 2021 | -12.73% |
| 2020 | -45.36% |
| 2019 | 103.37% |
| 2018 | -76.28% |
Continue Researching ZYNE
Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...